Viewing Study NCT06335290



Ignite Creation Date: 2024-05-06 @ 8:19 PM
Last Modification Date: 2024-10-26 @ 3:25 PM
Study NCT ID: NCT06335290
Status: RECRUITING
Last Update Posted: 2024-03-28
First Post: 2024-03-22

Brief Title: Radiotherapy Treatments for the Treatment of Thoracic District Tumors
Sponsor: European Institute of Oncology
Organization: European Institute of Oncology

Study Overview

Official Title: Radiotherapy Treatments for the Treatment of Thoracic District Tumors
Status: RECRUITING
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Evaluation of clinical and dosimetric aspects tolerance and effectiveness of thoracic radiotherapy treatments in patients undergoing radiotherapy for primary or secondary neoplasms localized in the thoracic anatomical region
Detailed Description: Approximately 60 of patients with neoplasms receive radiotherapy as part of their oncological treatment

Various primary tumors as well as metastases of various origins can be localized in the thoracic anatomical region

Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments

Treatment choice is usually established following multidisciplinary discussions based on disease characteristics and stage concurrent pathologies and pharmacological treatments patient preferences and functional aspects

The collection of data related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness aiming to identify the best treatment for these oncological pathologies This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms of the thoracic region for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None